<div id="readability-page-1">Massachusetts biotech companies are tightening their belts as economic uncertainty mounts, pulling in less funding, laying off workers and delaying acquisitions, per a new industry report. Why it matters: The state is one of the world's top producers of drugs treating rare diseases and other conditions, outpacing Chinese competitors. The mix of tariffs, federal funding cuts and other barriers may shrink the region's lead. Driving the news:...</div>

RARE

<p>Massachusetts biotech companies are facing economic challenges, leading to reduced funding, layoffs, and postponed acquisitions. The state, a leader in producing drugs for rare diseases, is at risk of losing its competitive edge due to tariffs, federal funding cuts, and other obstacles. This trend highlights the industry's struggle amid growing uncertainty.</p>

Mass. biotech industry shrinks amid headwinds, Trump cuts